# US 2020/0206141 A1 · Oral colon-targeted delivery system and preparation method and application thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2020/0206141 A1
- Document ID: US20200206141A1
- Status: Published application
- Kind: A1
- Application number: 16/461,564
- Filed: 2016-11-17
- Published: 2020-07-02
- Earliest claimed: 2016-11-17
- Assignees: Shanghai Jiaotong University School of Medicine
- Applicants: Shanghai Jiaotong University School of Medicine
- Inventors: Zeyu XIAO; Lei LU; Gaoxian CHEN; Miao LIN
- Web page: https://patentgrep.com/patent/US20200206141A1

## CPC

- A61K 9/4891: {Coated capsules; Multilayered drug free capsule shells (with drug coating for immediate release A61K9/4808; osmotic devices A61K9/0004)}
- A61K 47/6937: {the polymer being PLGA, PLA or polyglycolic acid}
- A61K 9/00: Medicinal preparations characterised by special physical form {(nuclear magnetic resonance contrast preparations or magnetic resonance imaging contrast preparations A61K49/18; preparations containing radioactive substances A61K51/12)}
- A61K 9/16: Agglomerates; Granulates; Microbeadlets {; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction (A61K9/20 takes precedence if the final form is a tablet; microspheres with drug-free outer coating, microcapsules A61K9/50; mixture of different granules, microcapsules, (coated) microparticles A61K9/5084; nanoparticles A61K9/51)}
- A61K 9/4816: {Wall or shell material}
- A61K 47/00: Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K 47/32: Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers {, poly(meth)acrylates, or polyvinyl pyrrolidone}
- A61K 47/36: Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K 47/40: Cyclodextrins; Derivatives thereof
- A61K 47/42: Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein (oligopeptides having up to five amino acids {A61K47/183}; polyamino acids A61K47/34)
- A61K 47/46: Ingredients of undetermined constitution or reaction products thereof, e.g. skin, bone, milk, cotton fibre, eggshell, oxgall or plant extracts
- A61K 47/6843: {the antibody targeting a material from animals or humans}
- A61K 47/6849: {the antibody targeting a receptor, a cell surface antigen or a cell surface determinant}
- A61P 1/00: Drugs for disorders of the alimentary tract or the digestive system
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

An oral colon-targeted delivery system is described, which includes a bacterial flora sensitive layer which contains polysaccharides and covers the exterior of active ingredients, a pH sensitive layer which contains any polymer composition dissolved under the condition of pH≥7 and covers the exterior of the bacterial flora sensitive layer. A preparation method and applications of the delivery system are also described. According to the oral colon-targeted delivery system combined with the pH sensitive and bacterial flora sensitive mechanisms, the selective dissolution and release of active ingredients in the colon site are effectively improved by using double-layer protection so that the therapeutic or diagnostic effect is enhanced, and the application prospect is broad.

## Claims

### Claim 1

An oral colon-targeted delivery system comprising:
a bacterial flora sensitive layer which contains polysaccharides and covers exterior active ingredients; and
a pH sensitive layer which contains any polymer composition dissolved under the condition of pH≥7 and covers the exterior of the bacterial flora sensitive layer.

### Claim 2 (depends on 1)

The oral colon-targeted delivery system according to claim 1, wherein the polysaccharides comprise β-cyclodextrin derivative and/or plant extracts and derivatives thereof.

### Claim 3 (depends on 1)

The oral colon-targeted delivery system according to claim 1, wherein the polymer compositions of the pH sensitive layer comprise components of the following weight percentages: 10%˜43% of methacrylic acid-methyl methacrylate copolymer, 5%˜36% of plasticizer and 5%˜22% of talcum powder.

### Claim 4 (depends on 1)

The oral colon-targeted delivery system according to claim 1, wherein the dosage forms of the delivery system comprise capsules, microcapsules, tablets, pills or granules.

### Claim 5 (depends on 1)

The oral colon-targeted delivery system according to claim 1, wherein the active ingredients comprise drugs and/or diagnostic reagents.

### Claim 6 (depends on 5)

The oral colon-targeted delivery system according to claim 5, wherein the drugs comprise protein drugs, antibody drugs, gene drug, chemical drugs, or nanodrugs.

### Claim 7 (depends on 5)

The oral colon-targeted delivery system according to claim 5, wherein the diagnostic reagents comprise an imaging reagent.

### Claim 8 (depends on 5)

The oral colon-targeted delivery system according to claim 5, wherein the drugs are in a targeted nanoparticle dosage form.

### Claim 9 (depends on 8)

The oral colon-targeted delivery system according to claim 8, wherein the targeted nanoparticles are PLGA-PEG nanoparticles modified by CD-98 antibody.

### Claim 10 (depends on 2)

The oral colon-targeted delivery system according to claim 2, wherein the plant extracts comprise celery extract, konjac gum or pectin.

### Claim 11 (depends on 2)

The oral colon-targeted delivery system according to claim 2, wherein the β-cyclodextrin derivative is a β-cyclodextrin polymer crosslinked with epichlorohydrin.

### Claim 12 (depends on 4)

The oral colon-targeted delivery system according to claim 4, wherein the preparation method of the delivery system of the capsule dosage form comprises the following steps:
dissolving polysaccharides in an organic solvent to obtain a solution, drawing a proper amount of the solution, adding into a capsule shell, drying at 45˜65° C. for 5˜15 hours, then cooling to room temperature, and obtaining the bacterial flora sensitive layer; and
preparing a coating fluid of the pH sensitive layer by mixing the polymer compositions dissolved under the condition of pH≥7, spraying on the outer surface of a capsule shell containing the bacterial flora sensitive layer, and obtaining the oral colon-targeted delivery system sensitive to both pH and bacterial flora after drying.

### Claim at position 13

-16. (canceled)

### Claim 17 (depends on 1)

A method of treating colonic diseases in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of the oral colon-targeted delivery system according to claim 1.

### Claim 18 (depends on 1)

A method of diagnosing colonic diseases in a subject in need thereof, comprising administering to the subject the oral colon-targeted delivery system according to claim 1.

### Claim 19 (depends on 1)

A method of treating and/or diagnosing colonic diseases in a subject in need thereof, comprising administering to the subject the oral colon-targeted delivery system according to claim 1.

### Claim 20 (depends on 17)

The method of treating colonic diseases according to claim 17, wherein the oral colon-targeted delivery system comprises one or more drugs and the one or more drugs are absorbed orally by the colon.
